June 15, 2017 (Shareholders Foundation) - An investigation on behalf of investors, who currently hold shares of Albany Molecular Research, Inc. (NASDAQ:AMRI), was announced concerning whether the takeover of Albany Molecular Research, Inc. by The Carlyle Group and GTCR LLC for $21.75 per share is unfair to NASDAQ:AMRI stockholders.


The investigation by a law firm concerns whether certain officers and directors of Albany Molecular Research, Inc. breached their fiduciary duties owed to NASDAQ:AMRI investors in connection with the proposed acquisition.

On June 6, 2017, Albany Molecular Research, Inc. (NASDAQ:AMRI) announced it has signed an agreement to be acquired by affiliates of The Carlyle Group and GTCR LLC for $21.75 per share in cash.

However, the investigation concerns whether the offer is unfair to NASDAQ:AMRI stockholders. More specifically, the investigation concerns whether the Albany Molecular Research Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.

Albany Molecular Research, Inc. reported that its annual Total Revenue rose from $402.36 million in 2015 to $570.45 million in 2016.

Shares of Albany Molecular Research, Inc. (NASDAQ:AMRI) reached in 2014 as high as $23.26 per share.